Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Others

Ratios

Protara Therapeutics (TARA) Acquisitions (2020)

Protara Therapeutics' Acquisitions history spans 1 years, with the latest figure at -$3.7 million for Q1 2020.

Quarterly Acquisitions changed N/A to -$3.7 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$3.7 million through Dec 2020, changed N/A year-over-year, with the annual reading at -$3.7 million for FY2020, N/A changed from the prior year.
Acquisitions came in at -$3.7 million for Q1 2020.
In the past five years, Acquisitions ranged from a high of -$3.7 million in Q1 2020 to a low of -$3.7 million in Q1 2020.